Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx is a clinical-stage biotechnology company that is poised for success with its innovative cell therapy approach in the treatment of various forms of cancer and other incurable diseases. The recently announced acquisition by collaborative partner Gilead for a significant sum further validates the potential of Arcellx's pipeline, particularly with the potential approval and successful launch of its lead candidate anito-cel in multiple myeloma patients. With a strong partnership and potential for significant long-term sales, Arcellx has a positive outlook for future growth and investors should continue to monitor its performance closely.

Bears say

Arcellx is facing significant risks that could negatively impact its valuation, including the loss of a key collaboration for anito-cel, potential competition for its lead programs and dilutive financing or acquisition risks. Additionally, its recent acquisition by Gilead may lead to pricing pressure from insurance companies and regulatory risks. While Arcellx has shown promising results with anito-cel, there is no guarantee it will gain market share in a competitive market for MM treatments.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.